@prefix dcterms: . @prefix this: . @prefix sub: . @prefix prov: . @prefix pav: . @prefix orcid: . @prefix codebase: . @prefix version: . @prefix instance: . @prefix process: . @prefix np: . @prefix rdfs: . @prefix xsd: . @prefix has-source: . @prefix d: . @prefix dv: . @prefix dr: . @prefix npx: . sub:head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:publicationInfo; a np:Nanopublication . } sub:assertion { d:DB00169 dv:ddi-interactor-in dr:DB00169_DB01083 . d:DB01083 dv:ddi-interactor-in dr:DB00169_DB01083 . dr:DB00169_DB01083 dcterms:identifier "drugbank_resource:DB00169_DB01083"; dcterms:title "DDI between Cholecalciferol and Orlistat - Orlistat may decrease the serum concentration of Vitamin D analogs. More specifically, orlistat may impair absorption of Vitamin D analogs such as cholecalciferol. Monitor clinical response (plasma calcium concentrations) to orally administered vitamin D analogs closely if used with orlistat. When this combination must be used, consider administering the vitamin D analog at least 2 hours before or after the administration of orlistat."@en; a dv:Drug-Drug-Interaction; rdfs:label "DDI between Cholecalciferol and Orlistat - Orlistat may decrease the serum concentration of Vitamin D analogs. More specifically, orlistat may impair absorption of Vitamin D analogs such as cholecalciferol. Monitor clinical response (plasma calcium concentrations) to orally administered vitamin D analogs closely if used with orlistat. When this combination must be used, consider administering the vitamin D analog at least 2 hours before or after the administration of orlistat. [drugbank_resource:DB00169_DB01083]"@en . } sub:provenance { sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 . } sub:publicationInfo { sub:signature.MCwCFHIgHwDkNUfR npx:hasPublicKey "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"; npx:hasSignature "MCwCFHIgHwDkNUfRwjju77sciJ/dIJ/PAhRQdixUTtbDmIIP5TtZLs3Gtb+WHg=="; npx:signedBy instance: . this: dcterms:created "2018-03-30T11:12:29.936+02:00"^^xsd:dateTime; dcterms:license ; npx:hasSignatureElement sub:signature.MCwCFHIgHwDkNUfR; prov:wasGeneratedBy process: . instance: prov:specializationOf codebase:; prov:wasAttributedTo orcid:0000-0002-1267-0234 . process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11"; prov:used version:; prov:wasAssociatedWith instance:; prov:wasStartedBy orcid:0000-0002-1267-0234 . version: dcterms:isVersionOf codebase:; pav:version "eda7951a5f6c622c5d2132f50c3093138484a349"; prov:wasAttributedTo orcid:0000-0002-1267-0234 . }